Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer
Go back to Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer| Astellas Pharma Inc Unsponsored ADR (AMEX: ALPMY) | Delayed: 13.16 -0.31 (2.3%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.47 | 52 Week High | $19.40 | |||
| Open | $13.07 | 52 Week Low | $12.50 | |||
| Day High | $13.16 | P/E | N/A | |||
| Day Low | $13.04 | EPS | $0.00 | |||
| Volume | 290,219 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 24.72 -0.36 (1.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.08 | 52 Week High | $37.39 | |||
| Open | $24.99 | 52 Week Low | $28.25 | |||
| Day High | $25.24 | P/E | 14.98 | |||
| Day Low | $24.69 | EPS | $1.65 | |||
| Volume | 81,942,663 | |||||
